STOCK TITAN
  1. Home
  2. Sec-filings
  3. ADGM
  4. [POS AM] Adagio Medical Holdings, Inc. SEC Filing

Accounting consent corrected as Adagio Medical (ADGM) files Post-Effective Amendment No. 2

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
POS AM

Rhea-AI Filing Summary

Adagio Medical Holdings, Inc. filed Post-Effective Amendment No. 2 to its Registration Statement (File No. 333-284263) to correct Exhibit 23.4, the consent of its independent registered public accounting firm. The amendment replaces an unsigned consent previously filed and makes no other changes to the registration statement or prospectus.

Positive

  • None.

Negative

  • None.

Insights

Correction fixes an administrative exhibit error without changing offering terms.

The amendment replaces an unsigned consent of WithumSmith+Brown, PC with the proper signed consent for Exhibit 23.4, as stated in the filing. This is an administrative correction limited to the exhibit and does not alter the prospectus text.

Stakeholders should expect no change to the registered securities' terms from this filing; subsequent filings will show substantive amendments if any arise.

Registration File No. 333-284263 Post-Effective Amendment No. 2
Commission File Number 001-42199 Adagio Medical Holdings, Inc.
IRS Employer ID 99-1151466 Company charter information
Amendment filing date April 2, 2026 Signature date on the amendment
Exhibit consent filing date January 14, 2025 Exhibit 5.1 / 23.1 filing date shown in exhibits table
Post-Effective Amendment regulatory
"This Post-Effective Amendment No. 2 to the Registration Statement on Form S-1"
A post-effective amendment is an official update to a securities registration document filed after that document has become effective with regulators; it corrects, adds or replaces information about the securities, the company, or an offering. Investors care because it keeps the legal record current and can change what is being sold or the rights attached to shares — like getting a revised product manual after a launch that may affect value or use.
Form S-1 on Form S-3 regulatory
"POST-EFFECTIVE AMENDMENT NO. 2 FORM S-1 ON FORM S-3 REGISTRATION STATEMENT"
Offering Type base_shelf_indeterminate
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

FAQ

What did Adagio Medical (ADGM) correct in Post-Effective Amendment No. 2?
The company corrected Exhibit 23.4 by replacing an unsigned consent with the signed consent of WithumSmith+Brown, PC. No other parts of the registration statement or prospectus were changed.

Does the amendment change the securities being registered in file 333-284263?
No, the amendment is limited to correcting an exhibit and does not modify the registration statement's securities or the prospectus that forms part of it.

When did Adagio Medical file this Post-Effective Amendment No. 2?
The amendment was signed and filed on April 2, 2026, according to the signature pages included in the filing.

Who signed the Post-Effective Amendment No. 2 for Adagio Medical?
Todd Usen signed on behalf of Adagio Medical Holdings, Inc.; the signature pages show multiple officers and directors executed the filing on April 2, 2026.

 

As filed with the United States Securities and Exchange Commission on April 2, 2026.
Registration No. 333-284263
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

POST-EFFECTIVE 

AMENDMENT NO. 2 

TO 

FORM S-1 

ON FORM S-3 

REGISTRATION STATEMENT 

UNDER 

THE SECURITIES ACT OF 1933

 

 

Adagio Medical Holdings, Inc. 

(Exact name of registrant as specified in its charter)

 

 

Delaware

(State or other jurisdiction of
incorporation organization)

001-42199

(Commission

File Number)

99-1151466

(I.R.S. Employer
Identification No.)

     
 

26051 Merit Circle, Suite 102

Laguna Hills, California 92653

(949) 348-1188

  

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

 

Todd Usen 

Chief Executive Officer 

26051 Merit Circle, Suite 102 

Laguna Hills, California 92653 

(949) 348-1188 

(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)

 

 

Copies to: 

Eric Blanchard
Paul Alexander
Cooley LLP
500 Boylston Street 

14th Floor
Boston, MA 02116
(617) 937-2300

 

 

 

Approximate date of commencement of proposed sale to the public: 

From time to time after the effective date of this registration statement.

 

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ¨

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: x

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

 

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(c) under the Securities Act, check the following box. ¨

 

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨ Accelerated filer ¨
Non-accelerated filer x Smaller reporting company x
    Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

 

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Post-Effective Amendment No. 2 to the Registration Statement on Form S-1 on Form S-3 (File No. 333-284263) (“Post-Effective Amendment No. 2”) of Adagio Medical Holdings, Inc. is being filed solely to amend the Post-Effective Amendment No. 1 to the Registration Statement filed with the U.S. Securities and Exchange Commission on April 1, 2026, to correct Exhibit 23.4, the Consent of Independent Registered Public Accounting Firm. The original filing mistakenly included an unsigned version of the consent of WithumSmith+Brown, PC. No other changes have been made to the Registration Statement. This Post-Effective Amendment No. 2 does not modify any provision of the prospectus that forms part of the Registration Statement and, accordingly, the prospectus has not been included herein. This Post-Effective Amendment No. 2 is not intended to amend or delete any part of the Registration Statement except as specifically noted herein.

 

 

 

 

PART II
INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 16. Exhibits

 

Exhibit 
Number 		  Description   Schedule/
Form 		   File No.    Exhibit    Filing Date
2.1†   Business Combination Agreement, dated as of February 13, 2024, by and among Aja HoldCo, Inc., ARYA Sciences Acquisition Corp IV, Aja Merger Sub 1, Aja Merger Sub 2, Inc. and Adagio Medical, Inc.   8-K   001- 42199   2.1   August 6, 2024
2.2   Consent and Amendment No. 1 to the Business Combination Agreement, dated as of June 25, 2024, by and among ARYA Sciences Acquisition Corp IV and Adagio Medical, Inc.   8-K   001- 42199   2.2   August 6, 2024
3.1   Amended and Restated Certificate of Incorporation of the Company.   8-K   001- 42199   3.1   August 6, 2024
3.2   Amended and Restated By-Laws of the Company.   8-K   001- 42199   3.2   August 6, 2024
4.1   Form of Base Warrant Agreement.   8-K   001- 42199   4.1   August 6, 2024
4.2   Form of Pre-Funded Warrant Agreement.   8-K   001- 42199   4.2   August 6, 2024
4.3   Form of Convert Warrant Agreement.   8-K   001- 42199   4.3   August 6, 2024
4.4   Specimen Common Stock Certificate.   8-K   001- 42199   4.4   August 6, 2024
5.1   Opinion of Reed Smith LLP.   S-1   333-284266   5.1   January 14, 2025
10.1   Form of Convertible Security Subscription Agreement.   8-K   001- 42199   10.1   August 6, 2024
10.2   Form of Adagio Holdings Stockholder Transaction Support Agreement.   8-K   001-42199   10.4   August 6, 2024
10.3   Convert Guaranty, dated as of July 31, 2024, by and among Adagio Medical and the other parties thereto.   8-K   001- 42199   10.9   August 6, 2024
10.4   Convert Security Document, dated as of July 31, 2024, by and among Adagio Holdings, Adagio Medical and the other parties thereto.   8-K   001- 42199   10.10   August 6, 2024
10.5   Registration Rights Agreement dated as of July 31, 2024, by and among Adagio Medical, Perceptive Life Sciences Master Fund, Ltd. and the other parties thereto.   8-K   001- 42199   10.11   August 6, 2024
10.6   Form of Adagio Holdings Convertible Note.   8-K   001- 42199   10.12   August 6, 2024
10.7   Form of Non-Redemption Subscription Agreement.   8-K   001- 42199   10.13   August 6, 2024
10.8   Form of Open Market Purchase Subscription Agreement.   8-K   001- 42199   10.14   August 6, 2024
10.9   Form of Subscription Agreement with Pre-Funded Warrant and PIPE Warrant.   8-K   001- 42199   10.15   August 6, 2024
10.10   PIPE Subscription Agreement, by and among the Perceptive PIPE Investor, Adagio and ARYA.   8-K   001- 42199   10.16   August 6, 2024

 

 

 

 

Exhibit 
Number 		  Description   Schedule/
Form 		   File No.    Exhibit    Filing Date
10.11   Amendment to PIPE Subscription Agreement, by and among the Perceptive PIPE Investor, Adagio and ARYA.   8-K   001- 42199   10.17   August 6, 2024
10.12   Amended and Restated Subscription Agreement, by and among the Perceptive PIPE Investor, Adagio and ARYA.   8-K   001- 42199   10.18   August 6, 2024
10.13   Form of Amended and Restated Subscription Agreement with Pre-Funded Warrant and Warrant.   8-K   001- 42199   10.19   August 6, 2024
10.14   Form of Amended and Restated Open Market Purchase Subscription Agreement.   8-K   001- 42199   10.20   August 6, 2024
10.15   Form of Amended and Restated Non-Redemption Subscription Agreement.   8-K   001- 42199   10.21   August 6, 2024
10.16   2024 Bridge Financing Note Subscription Agreement, dated as of February 13, 2024, by and between ListCo, the Perceptive PIPE Investor and certain other investors thereto   8-K   001- 42199   10.22   August 6, 2024
10.17   Form of Convert Waiver   8-K   001-42199   10.1   January 6, 2025
23.1   Consent of Reed Smith LLP (included as part of Exhibit 5.1).   S-1   333-284266   5.1   January 14, 2025
23.2*   Consent of WithumSmith+Brown, PC, independent registered public accounting firm for Adagio Medical Holdings, Inc.                
24.1   Power of Attorney.   S-1   333-284266   24.1   January 14, 2025

  

* Filed herewith.

 

† Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601. The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

 

# Indicates a management contract or compensatory plan, contract or arrangement.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 2 to Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in Laguna Hills, California, on this 2nd day of April, 2026.

 

ADAGIO MEDICAL HOLDINGS, INC.  
     
By: /s/ Todd Usen  
  Name: Todd Usen  
  Title: Chief Financial Officer  

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

 

 

 

Signature   Title   Date
         
/s/ Todd Usen   Chief Executive Officer and Director   April 2, 2026
Todd Usen   (Principal Executive Officer)    
         
/s/ Deborah Kaster   Chief Financial Officer   April 2, 2026
Deborah Kaster   (Principal Financial Officer and Principal Accounting Officer)    
         
*   Director   April 2, 2026
James L. Cox        
         
*   Director   April 2, 2026
Orly Mishan        
         
*   Director   April 2, 2026
Keyvan Mirsaeedi-Farahani        
         
*   Director   April 2, 2026
Timothy Moran        
         
*   Director   April 2, 2026
Sandra Gardiner        

 

/s/ Todd Usen        
Todd Usen        
Attorney-in-fact        

 

 

 

Source: View Original Filing on SEC EDGAR